St. John’s-based Sequence Bio, which uses genomic data to improve drug discovery, announced last week the approval of the NB Genome Project Pilot in partnership with three doctors in Moncton.
The main thrust of Sequence Bio’s mission so far has been to lead a large-scale genetic research project in Newfoundland and Labrador, to be called the NL Genome Project. This community-based initiative aims to create a powerful drug-discovery platform to help with the identification of diseases and the drugs that could treat them.
The New Brunswick pilot project will be the company’s first genomic research project. Meanwhile, Newfoundland and Labrador is proceeding with the formation of a board to review genetic and genomic research. Once that board is formed, Sequence plans to submit its proposed NL Genome Project Pilot and proceed with its research in its home province.
Read more at Entrevestor.